Lv41
618 积分 2024-04-18 加入
Personalized treatment approach for HER2-positive metastatic breast cancer
4天前
已完结
Discordance of human epidermal growth factor receptor 2‐low status between breast primary and distant metastases with clinical–pathological correlation
19天前
已完结
Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study
1个月前
已完结
Effectiveness of trastuzumab deruxtecan rechallenge in a patient with HER2-positive metastatic breast cancer: a case report
1个月前
已完结
Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
2个月前
已关闭
Prognostic factors of patients with human epidermal growth factor receptor 2-positive breast cancer following neoadjuvant therapy: Development and validation of a predictive nomogram
2个月前
已完结
Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy
3个月前
已关闭
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
3个月前
已完结
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments
4个月前
已完结
Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment
4个月前
已完结
皖公网安备34019202002308
